Potential impact of nirsevimab and bivalent maternal vaccine against RSV bronchiolitis in infants: A population-based modelling study

• Hauptverfasser: Mónica López-Lacort (Verfasst von), Ana Corberán-Vallet (Verfasst von), Francisco J. Santonja (Verfasst von), Cintia Muñoz-Quiles (Verfasst von), Javier Díez-Domingo (Verfasst von), Alejandro Orrico-Sánchez (Verfasst von)
• Format: Buch
• Veröffentlicht: Elsevier, 2024-08-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: A new monoclonal antibody (nirsevimab; Beyfortus®) and a bivalent prefusion RSV vaccine (Abrysvo®) for maternal immunization have been approved recently. This is a modelling study to estimate the potential impact of different immunization programs with these products on RSV-bronchiolitis...